Mesoblast (MESO) Competitors $10.79 -0.07 (-0.64%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$10.79 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, KRYS, CYTK, and ZLABShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Cytokinetics (CYTK), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Nuvalent Telix Pharmaceuticals Axsome Therapeutics ADMA Biologics Akero Therapeutics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech Cytokinetics Zai Lab Nuvalent (NASDAQ:NUVL) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends. Is NUVL or MESO more profitable? Mesoblast's return on equity of 0.00% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -31.35% -29.27% Mesoblast N/A N/A N/A Does the media favor NUVL or MESO? In the previous week, Nuvalent had 2 more articles in the media than Mesoblast. MarketBeat recorded 8 mentions for Nuvalent and 6 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.71 beat Nuvalent's score of 0.38 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in NUVL or MESO? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer NUVL or MESO? Nuvalent presently has a consensus price target of $119.60, suggesting a potential upside of 48.82%. Mesoblast has a consensus price target of $18.00, suggesting a potential upside of 66.82%. Given Mesoblast's higher possible upside, analysts clearly believe Mesoblast is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, NUVL or MESO? Nuvalent has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Which has better earnings and valuation, NUVL or MESO? Mesoblast has higher revenue and earnings than Nuvalent. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.39-18.31Mesoblast$5.90M233.69-$87.96MN/AN/A SummaryMesoblast beats Nuvalent on 8 of the 13 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$2.92B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.5627.6520.23Price / Sales233.69283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book2.567.538.035.65Net Income-$87.96M-$55.14M$3.18B$249.15M7 Day Performance-0.92%4.22%2.88%2.91%1 Month Performance-8.48%0.91%1.67%4.11%1 Year Performance39.41%5.40%34.39%20.98% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast2.3364 of 5 stars$10.79-0.6%$18.00+66.8%+39.4%$1.38B$5.90M0.0080NUVLNuvalent3.7165 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.48BN/A-17.3840Insider TradeTLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.44B$516.72M0.00N/AAXSMAxsome Therapeutics4.7484 of 5 stars$104.39+1.0%$172.33+65.1%+28.5%$5.14B$432.16M-18.09380Trending NewsAnalyst ForecastAnalyst RevisionADMAADMA Biologics4.1503 of 5 stars$18.21+0.3%$27.67+51.9%+59.6%$4.35B$426.45M21.42530Positive NewsAKROAkero Therapeutics3.4504 of 5 stars$53.36-5.0%$82.50+54.6%+142.5%$4.25BN/A-27.3630Insider TradePCVXVaxcyte1.7706 of 5 stars$32.51-0.2%$136.50+319.9%-57.3%$4.19BN/A-8.15160News CoverageRYTMRhythm Pharmaceuticals3.8115 of 5 stars$63.19+0.7%$77.31+22.3%+55.6%$4.02B$136.86M-22.49140News CoverageKRYSKrystal Biotech4.5831 of 5 stars$137.46-1.0%$211.13+53.6%-22.4%$3.97B$333.45M33.04210News CoverageAnalyst RevisionCYTKCytokinetics3.9282 of 5 stars$33.04-0.4%$70.92+114.7%-38.9%$3.95B$18.47M-6.25250ZLABZai Lab3.4092 of 5 stars$34.97+0.7%$54.28+55.2%+110.3%$3.88B$398.99M-14.041,869News CoverageInsider TradeAnalyst RevisionGap Up Related Companies and Tools Related Companies NUVL Competitors TLX Competitors AXSM Competitors ADMA Competitors AKRO Competitors PCVX Competitors RYTM Competitors KRYS Competitors CYTK Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MESO Stock Alerts